Last reviewed · How we verify
NCT03839173: MedolacHMF
Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet
NA trial testing Human milk based human milk fortifier in Premature Infant in 51 participants. Status unknown.
31 March 2020
Quick facts
| Lead sponsor | Augusta University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 25 July 2019 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Human milk based human milk fortifier
Conditions studied
- Premature Infant — all drugs for Premature Infant →
- Breast Milk Expression — all drugs for Breast Milk Expression →
Sponsor
Augusta University
Who can join
Adults 23 Weeks to 33 Weeks, any sex, with Premature Infant or Breast Milk Expression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this two-arm investigation is to determine if growth patterns of very low birth weight infants (VLBW) (birth weight 750-1500 grams) fed human milk (maternal or donor) supplemented with a human milk-based fortifier grow according to established guidelines and maintain adequate micronutrient levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03839173
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Premature Infant
Currently open trials in the same condition.
- NCT07410858 — Virtual Reality-Enhanced Parent Education in Neonatal Intensive Care · NA · recruiting
- NCT07052786 — Development and Effectiveness Evaluation of a Clustered Care Guideline Within Individualized Developmental Care: RCT · NA · recruiting
- NCT06212427 — Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs) · NA · recruiting
- NCT07100353 — Premature Infants' Developmental Function, Daily Living, Participation, and Quality of Life: A Longitudinal Study · active not recruiting
- NCT03825835 — 30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants · NA · recruiting
Other Augusta University trials
Trials by the same sponsor.
- NCT07341841 — Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study · NA · enrolling by invitation
- NCT07489144 — CO-creating Novel, Feasible, and Inclusive Research Methods · NA · active not recruiting
- NCT06514014 — Transition From Donor Milk: a Feasibility Study · NA · recruiting
- NCT06907992 — A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated C · not yet recruiting
- NCT06058169 — Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03839173 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Augusta University
- Last refreshed: 29 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03839173.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing